CTLA-4 and PD-1:the potential immunotherapeutic targets for malignant lymphoma
10.3760/cma.j.issn.0254-5101.2016.10.013
- VernacularTitle:CTLA-4和PD-1：恶性淋巴瘤免疫治疗中潜在的作用靶点
- Author:
Xiaohui JIA
;
Xianhuo WANG
;
Huilai ZHANG
- Publication Type:Journal Article
- Keywords:
Immune checkpoint;
CTLA-4;
PD-1;
PD-L1;
Immunotherapy;
Tumor microenviron-ment;
Malignant lymphoma
- From:
Chinese Journal of Microbiology and Immunology
2016;36(10):783-789
- CountryChina
- Language:Chinese
-
Abstract:
The human immune system has the regulatory functions of eradicating pathogens and limiting excessive inflammation, which protect the surrounding tissue from being damaged. The immune bal-ance of self-limiting is mainly controlled by complex interactions between antigen-presenting cells ( APCs ) and T cells. However, the immune balance is destroyed in cancer, which results in immune evasion and tumor metastasis or promotes the development of drug resistance. Immune checkpoints play critical roles in the immune system. Therefore, blocking tumor immune evasion by targeting the immune checkpoints has be-come a research focus in the treatment of relapsed or refractory malignant tumors. Currently, in the studies of malignant lymphomas, some phaseⅠ/Ⅱclinical studies of immune checkpoint inhibitors have achieved sur-prising results. This review will discuss the regulation and immunotherapy of immune checkpoints in malig-nant lymphomas.
